Chi­na's Abo­gen, a small mR­NA up­start, sets a biotech record with mam­moth $700M Se­ries C

A lit­tle-known start­up from Chi­na shocked the biotech world Thurs­day with a record-break­ing Se­ries C, show­ing how deep-pock­et­ed in­vestors are an­gling to get a piece …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER